SAB Biotherapeutics (SABS) Live Share Price, Invest From India

SAB Biotherapeutics Stock Performance

as on October 9, 2026 at 2:15 pm IST

Day's Low
Day's High
$2.76
Day's Price Range
$2.93
$2.89
4.50%
Downside
1.38%
Upside
52 Week's Low
52 Week's High
$2.10
52-Week Price Range
$5.15
$2.89
27.34%
Downside
78.20%
Upside

SAB Biotherapeutics share price movements today

Previous Close: $2.88
Open: $2.91
Volume: 1.4M
Market Cap: $262.0M
Day's Low - High: $2.76 - $2.93
52 Week Low - High: $2.10 - $5.15

SAB Biotherapeutics Historical Returns

1 Month Return: -16.95 %
3 Month Return: -27.02 %
1 Year Return: + 15.6 %
3 Year Return: -59.21 %
5 Year Return: 0 %

SAB Biotherapeutics Stock Fundamentals & Key Indicators

Check SAB Biotherapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$262.0M

EPS (TTM)

3.5702

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.60%

PE Ratio (TTM)

0.81

Industry PE ratio

-6.50

PEG Ratio

0.00

EBITDA

-9.4M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-6.74%

SAB Biotherapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of SAB Biotherapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
SAB Biotherapeutics	Buy	$262.0M	NA	0.81	0.00%	0.00%
Moderna	Neutral	$78.4B	-35.39%	-24.62	-12.57%	0.00%
Vertex Pharmaceuticals	StrongBuy	$128.2B	181.24%	29.19	86.04%	0.00%
Regeneron	Buy	$76.1B	34.46%	17.72	84.86%	0.50%

Stock Returns calculator for SAB Biotherapeutics Stock including INR - Dollar returns

The SAB Biotherapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

SAB Biotherapeutics investment value today

Current value as on today

₹1,25,830

Returns

₹25,830

(+25.83%)

Returns from SAB Biotherapeutics Stock

₹15,600 (+15.6%)

Dollar Impact

₹10,230 (+10.23%)

Analyst Recommendation on SAB Biotherapeutics Stock

Based on 8 analysts

BUY

87.50%

Buy

12.50%

Hold

0.00%

Sell

Based on 8 analysts, 87.5% of analysts recommend a 'BUY' rating for SAB Biotherapeutics. Average target price of $11.64

SAB Biotherapeutics Share Price Target

Get share price movements and forecasts by analysts on SAB Biotherapeutics.

What analysts predicted

75.17%UPSIDE

Target Price

$11.64

Current Price

$2.89

Analyzed by

8 Analysts

Target

$11.64

SAB Biotherapeutics target price $11.64, a slight upside of 75.17% compared to current price of $2.89. According to 8 analysts rating.

Indian Investors' Interest in SAB Biotherapeutics Stock

Search interest for SAB Biotherapeutics Stock has increased by 14% in the last 30 days, reflecting an upward trend in search activity.

Time period: September 9, 2026 to October 9, 2026

Change:14% versus previous 30 day period

SAB Biotherapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Revenue	0	0	0	-	-	-	-	-	-	-
Gross Profit	0	-1	0	0	-7	0	0	0	0	-
Operating Income	-18	-11	-10	-11	-10	-9	-12	-15	-19	-23
EBITDA	-21	-2	-6	-9	-4	-9	46	-16	-18	-21
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	1	1	0	0	0	0	0	0	0
Income Before Tax	-22	-5	-7	-10	-5	-10	45	-16	-18	-22
Income Tax Expense	-	-	-	-	-	-	-	-	-	-
Net Income	-22	-5	-7	-10	-5	-10	45	-16	-18	-22
Net Profit Margin	-209.50%	-110.12%	-288.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

SAB Biotherapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Mar 2023	Dec 2023	Mar 2025	Dec 2025
Total Revenue	3	55	60	23	2	1	-
Gross Profit	3	55	59	20	-1	-3	-3
Operating Income	-8	20	-13	-28	-38	-42	-48
EBITDA	-8	21	-15	-15	-38	-28	16
Interest Expense	0	0	0	0	0	0	0
Depreciation	0	0	1	3	3	4	3
Income Before Tax	-8	20	-17	-18	-42	-34	13
Income Tax Expense	-	-	-	0	-	-	-
Net Income	-8	20	-17	-18	-42	-34	13
Net Profit Margin	100.00%	100.00%	97.28%	86.23%	-67.26%	-262.41%	0.00%

SAB Biotherapeutics Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Net Income	-22	-5	-7	-10	-5	-10	5	-16	-18	-41
Operating Cash Flow	-13	-10	-7	-6	-7	-7	-13	-16	-14	-24
Investing Cash Flow	0	-31	11	-1	4	5	-129	-1	-65	-70
Financing Cash Flow	67	0	0	0	0	0	168	0	89	92
Change in Cash	54	-42	3	-8	-3	-1	25	-18	10	-2

SAB Biotherapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Mar 2023	Dec 2023	Mar 2025	Dec 2025
Net Income	-8	20	-17	-18	-42	-34	13
Operating Cash Flow	-9	10	1	-23	-25	-34	-44
Investing Cash Flow	0	-12	-10	-2	0	-11	-121
Financing Cash Flow	3	8	35	1	66	-1	168
Change in Cash	-6	6	26	-24	41	-47	1

Global Institutional Holdings in SAB Biotherapeutics

Check out the Institutions with significant holdings in SAB Biotherapeutics.

Funds	Holdings
Joseph Edelman	7.28%
Peter Kolchinsky	4.84%
Vanguard	3.52%
VANGUARD INDEX FUNDS	2.67%
iShares	2.18%

See all

Insights on SAB Biotherapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, -410.0 → 114.69K (in $), with an average increase of 100.4% per quarter
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 615.6% return, outperforming this stock by 600.0%
NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 93.4% return, outperforming this stock by 152.6%
NEGATIVE IMPACT
Price Dip
In the last 1 month, SABS stock has moved down by -17.0%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 4 quarters, 45.44M → -22.49M (in $), with an average decrease of 56.1% per quarter

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Organisation	SAB Biotherapeutics
Headquarters	777 W 41st St., Miami Beach, FL, 33140, US
Industry	Biotechnology
CEO	Samuel J. Reich

Key Management of SAB Biotherapeutics

Name	Title
Ms. Lucy To	Executive VP & CFO
Dr. Christoph Bausch M.B.A., Ph.D.	Executive VP & COO
Dr. Eddie Joe Sullivan Ph.D.	Co-Founder, President & Director
Dr. Alexandra Kropotova M.B.A., M.D.	Executive VP & Chief Medical Officer
Ms. Catherine DeRose	Vice President of Human Resources
Ms. Hua Wu Ph.D.	Senior Vice President of Product Development
Dr. Carlos N. Carillo M.Sc., Ph.D.	Senior Vice President of Regulatory Affairs
Ms. Angie Parizek	Senior Vice President of Clinical Operations
Mr. Samuel J. Reich	CEO & Director

FAQs

What is SAB Biotherapeutics share price today?

SAB Biotherapeutics share price today is $2.89 as on October 9, 2026 at 8:45 am IST at the close of the market. SAB Biotherapeutics share today touched a day high of $2.93 and a low of $2.76.

What is the 52 week high and 52 week low for SAB Biotherapeutics share?

SAB Biotherapeutics share touched a 52 week high of $5.15 on March 12, 2026 and a 52 week low of $2.10 on October 17, 2025. SAB Biotherapeutics stock price today i.e. October 9, 2026 at 8:45 am IST is closed at $2.89,which is 43.88% down from its 52 week high and 37.62% up from its 52 week low.

What is SAB Biotherapeutics's market capitalisation today?

SAB Biotherapeutics market capitalisation is $0.00T as on October 9, 2026 at 8:45 am IST.

How to invest in SAB Biotherapeutics Stock (SABS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for SAB Biotherapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy SAB Biotherapeutics Stock (SABS) from India?

Indian investors can start investing in SAB Biotherapeutics (SABS) shares with as little as ₹96.730003356934 or $1 (as of October 9, 2026 at 6:43 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹967.30 in SAB Biotherapeutics stock (as per the Rupee-Dollar exchange rate as on October 9, 2026 at 6:43 pm IST). Based on SAB Biotherapeutics share’s latest price of $2.89 as on October 9, 2026 at 8:45 am IST, you will get 3.4602 shares of SAB Biotherapeutics. Learn more about fractional shares .